Does the media refer more to ADMA or LGND?

In the previous week, ADMA Biologics had 32 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 44 mentions for ADMA Biologics and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.29 beat ADMA Biologics' score of 0.09 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 6 Very Positive mention(s) 1 Positive mention(s) 33 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Neutral Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ANIP or LGND?

In the previous week, Ligand Pharmaceuticals had 8 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.80 beat Ligand Pharmaceuticals' score of 0.29 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor LGND or NBIX?

In the previous week, Neurocrine Biosciences had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 12 mentions for Ligand Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.73 beat Ligand Pharmaceuticals' score of 0.29 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Neurocrine Biosciences 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EXEL or LGND?

In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than Exelixis. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 5 mentions for Exelixis. Exelixis' average media sentiment score of 1.35 beat Ligand Pharmaceuticals' score of 0.29 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LGND or IONS?

In the previous week, Ionis Pharmaceuticals had 5 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 17 mentions for Ionis Pharmaceuticals and 12 mentions for Ligand Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.81 beat Ligand Pharmaceuticals' score of 0.29 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 9 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ligand Pharmaceuticals (LGND) Competitors

$274.88 +11.74 (+4.46%)

Closing price 04:00 PM Eastern

Extended Trading

$274.88 0.00 (0.00%)

As of 04:24 PM Eastern

Compare

LGND vs. ADMA, ANIP, NBIX, EXEL, and IONS

Should you buy Ligand Pharmaceuticals stock or one of its competitors? MarketBeat compares Ligand Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.78	$146.93M	$0.68	12.22
Ligand Pharmaceuticals	$274.48M	20.07	$124.45M	$7.37	37.30

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 55.95% compared to ADMA Biologics' net margin of 32.43%. ADMA Biologics' return on equity of 39.98% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

ADMA Biologics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

ADMA Biologics currently has a consensus target price of $19.67, indicating a potential upside of 136.66%. Ligand Pharmaceuticals has a consensus target price of $257.71, indicating a potential downside of 6.24%. Given ADMA Biologics' higher possible upside, research analysts plainly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, ADMA Biologics had 32 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 44 mentions for ADMA Biologics and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.29 beat ADMA Biologics' score of 0.09 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	6 Very Positive mention(s)	1 Positive mention(s)	33 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

ANI Pharmaceuticals presently has a consensus price target of $107.33, suggesting a potential upside of 35.03%. Ligand Pharmaceuticals has a consensus price target of $257.71, suggesting a potential downside of 6.24%. Given ANI Pharmaceuticals' higher possible upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Ligand Pharmaceuticals has a net margin of 55.95% compared to ANI Pharmaceuticals' net margin of 9.98%. ANI Pharmaceuticals' return on equity of 27.51% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Ligand Pharmaceuticals has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$923.71M	1.96	$78.34M	$3.95	20.12
Ligand Pharmaceuticals	$274.48M	20.07	$124.45M	$7.37	37.30

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Ligand Pharmaceuticals had 8 more articles in the media than ANI Pharmaceuticals. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 4 mentions for ANI Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.80 beat Ligand Pharmaceuticals' score of 0.29 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Summary

Ligand Pharmaceuticals beats ANI Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Ligand Pharmaceuticals (NASDAQ:LGND) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

In the previous week, Neurocrine Biosciences had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 13 mentions for Neurocrine Biosciences and 12 mentions for Ligand Pharmaceuticals. Neurocrine Biosciences' average media sentiment score of 0.73 beat Ligand Pharmaceuticals' score of 0.29 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals presently has a consensus target price of $257.71, indicating a potential downside of 6.24%. Neurocrine Biosciences has a consensus target price of $187.52, indicating a potential upside of 18.47%. Given Neurocrine Biosciences' higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87

Neurocrine Biosciences has higher revenue and earnings than Ligand Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$274.48M	20.07	$124.45M	$7.37	37.30
Neurocrine Biosciences	$3.10B	5.13	$478.60M	$6.49	24.39

Ligand Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Summary

Neurocrine Biosciences beats Ligand Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, Ligand Pharmaceuticals had 7 more articles in the media than Exelixis. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 5 mentions for Exelixis. Exelixis' average media sentiment score of 1.35 beat Ligand Pharmaceuticals' score of 0.29 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Exelixis has higher revenue and earnings than Ligand Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.62	$782.57M	$3.01	17.25
Ligand Pharmaceuticals	$274.48M	20.07	$124.45M	$7.37	37.30

Ligand Pharmaceuticals has a net margin of 55.95% compared to Exelixis' net margin of 35.08%. Exelixis' return on equity of 39.89% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Exelixis presently has a consensus price target of $47.35, suggesting a potential downside of 8.78%. Ligand Pharmaceuticals has a consensus price target of $257.71, suggesting a potential downside of 6.24%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Ligand Pharmaceuticals beats Exelixis on 10 of the 17 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Ionis Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Ionis Pharmaceuticals' net margin of -30.91%. Ligand Pharmaceuticals' return on equity of 16.19% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Ionis Pharmaceuticals	-30.91%	-58.65%	-10.07%

Ligand Pharmaceuticals has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$274.48M	20.07	$124.45M	$7.37	37.30
Ionis Pharmaceuticals	$1.06B	11.58	-$381.39M	-$2.07	N/A

In the previous week, Ionis Pharmaceuticals had 5 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 17 mentions for Ionis Pharmaceuticals and 12 mentions for Ligand Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.81 beat Ligand Pharmaceuticals' score of 0.29 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals currently has a consensus price target of $257.71, suggesting a potential downside of 6.24%. Ionis Pharmaceuticals has a consensus price target of $101.80, suggesting a potential upside of 37.34%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Ionis Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Ligand Pharmaceuticals beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.51B	$3.39B	$6.40B	$12.59B
Dividend Yield	N/A	2.27%	2.67%	5.69%
P/E Ratio	37.30	19.56	24.51	24.46
Price / Sales	20.07	325.83	553.73	123.18
Price / Cash	32.51	125.35	43.94	55.48
Price / Book	5.32	8.16	10.70	6.58
Net Income	$124.45M	$23.89M	$3.57B	$337.29M
7 Day Performance	7.98%	2.55%	0.56%	0.55%
1 Month Performance	32.22%	4.97%	3.57%	4.43%
1 Year Performance	139.78%	53.51%	28.49%	31.16%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	2.4391 of 5 stars	$274.88 +4.5%	$257.71 -6.2%	+133.8%	$5.51B	$274.48M	37.30	80	Insider Trade High Trading Volume
ADMA ADMA Biologics	4.4944 of 5 stars	$8.21 -1.3%	$19.67 +139.5%	-55.4%	$1.90B	$510.17M	12.07	530	Trending News
ANIP ANI Pharmaceuticals	4.145 of 5 stars	$81.68 +0.0%	$107.33 +31.4%	+27.1%	$1.86B	$923.71M	20.68	600
NBIX Neurocrine Biosciences	4.332 of 5 stars	$159.76 -1.8%	$187.52 +17.4%	+27.3%	$16.06B	$3.10B	24.62	2,000
EXEL Exelixis	2.9316 of 5 stars	$53.13 -0.7%	$47.35 -10.9%	+26.8%	$13.35B	$2.32B	17.65	1,077	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, NBIX, EXEL, and IONS

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Summary

How does Ligand Pharmaceuticals compare to Exelixis?

Summary

How does Ligand Pharmaceuticals compare to Ionis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, NBIX, EXEL, and IONS

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Which has preferable valuation and earnings, ADMA or LGND?

Do institutionals and insiders have more ownership in ADMA or LGND?

Is ADMA or LGND more profitable?

Which has more volatility & risk, ADMA or LGND?

Do analysts rate ADMA or LGND?

Does the media refer more to ADMA or LGND?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Do analysts rate ANIP or LGND?

Is ANIP or LGND more profitable?

Which has stronger earnings and valuation, ANIP or LGND?

Do institutionals & insiders hold more shares of ANIP or LGND?

Does the media prefer ANIP or LGND?

Which has more volatility and risk, ANIP or LGND?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Does the media favor LGND or NBIX?

Do analysts rate LGND or NBIX?

Which has preferable earnings & valuation, LGND or NBIX?

Which has more risk & volatility, LGND or NBIX?

Do insiders & institutionals believe in LGND or NBIX?

Is LGND or NBIX more profitable?

Summary

How does Ligand Pharmaceuticals compare to Exelixis?

Does the media prefer EXEL or LGND?

Which has more risk and volatility, EXEL or LGND?

Do insiders and institutionals hold more shares of EXEL or LGND?

Which has preferable valuation & earnings, EXEL or LGND?

Is EXEL or LGND more profitable?

Do analysts rate EXEL or LGND?

Summary

How does Ligand Pharmaceuticals compare to Ionis Pharmaceuticals?

Do insiders & institutionals hold more shares of LGND or IONS?

Which has more volatility and risk, LGND or IONS?

Is LGND or IONS more profitable?

Which has stronger earnings and valuation, LGND or IONS?

Does the media prefer LGND or IONS?

Do analysts rate LGND or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools